The overarching goal of the Einstein/Rockefeller/CUNY CFAR (ERC-CFAR) Developmental Core is to support the career development of early stage investigators (ESIs) of the three participating institutions through an effective mentoring process coupled with a peer-reviewed Catalytic grants program and ongoing support for their scientific growth via their participation in programs specifically tailored for ESIs. The objectives of the ERC-CFAR Developmental core are centered on mentoring ESIs, catalyzing trans-institutional collaborative HIV/AIDS research in the ERC-CFAR, supporting Scientific Working Group (SWG) efforts to catalyze research in their topic areas, facilitating scientific communication among ERC-CFAR investigators and enhancing international HIV/AIDS research. We will accomplish these goals through the following six specific Aims.
In Aim 1 we will provide individually tailored mentoring to ESIs and facilitate their development into independently funded researchers by pairing ESIs with established investigators (EIs), by providing both individual and group- level mentoring to help them develop NIH K- or R- type grants and by assisting senior level ESIs with transition to an R01 funding.
In Aim 2, we will support ESIs engaged in AIDS research in the ERC-CFAR via catalytic and micro grants, which will also be used to promote trans-institutional collaborations and to support SWG priorities.
In Aim 3, we will stimulate intra- and trans-institutional, collaborative AIDS research at the participating institutions by awarding joint catalytic grants. We will proactively recruit non-AIDS EIs engaged in cutting edge research into AIDS research.
In Aim 4, we will facilitate scientific communication among ERC- CFAR investigators by organizing a bi-weekly Trans-institutional ERC-CFAR research seminar series and the biweekly Clinical AIDS Grand Rounds series both of which are simulcast to all three institutions, ERC-CFAR Invited Speaker Seminars and Annual ERC-CFAR Scientific Retreats to foster scientific interaction.
In Aim 5, we will promote AIDS Research in the ERC-CFAR via integration with other Einstein programs such as WIHS, the institutional AIDS T32 and the Geographic Medicine T32 programs and African HIV/AIDS research programs.
In Aim 6, we will facilitate and mentor ESIs in conducting community participatory and behavioral AIDS research via collaboration with the Behavioral Science Core.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine, Inc
United States
Zip Code
Bhalakia, Avni M; Talib, Hina J; Choi, Jaeun et al. (2018) Acceptance of Routine HIV Testing by Hospitalized Adolescents and Young Adults. Hosp Pediatr 8:187-193
Hannaford, Alisse; Lipshie-Williams, Madeleine; Starrels, Joanna L et al. (2018) The Use of Online Posts to Identify Barriers to and Facilitators of HIV Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men: A Comparison to a Systematic Review of the Peer-Reviewed Literature. AIDS Behav 22:1080-1095
Lu, Ching-Lan; Pai, Joy A; Nogueira, Lilian et al. (2018) Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A 115:E11341-E11348
Grov, Christian; Jonathan Rendina, H; Patel, Viraj V et al. (2018) Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey. AIDS Behav 22:2743-2755
Cohen, Yehuda Z; Lorenzi, Julio C C; Krassnig, Lisa et al. (2018) Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med 215:2311-2324
Cohen, Yehuda Z; Lorenzi, Julio C C; Seaman, Michael S et al. (2018) Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol 92:
Cohen, Yehuda Z; Caskey, Marina (2018) Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS 13:366-373
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Liu, Yanyan; Ndumnego, Okechukwu C; Chen, Tingting et al. (2018) Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis. Pathogens 7:
Bar-On, Yotam; Gruell, Henning; Schoofs, Till et al. (2018) Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24:1701-1707

Showing the most recent 10 out of 27 publications